Biotech Values

[poorgradstudent]

benefit of a big name partner seem to be muted by the deal terms involving ARRY paying up for some development costs

I guess it depends on what the actual split and burden are, but note that this is what has put ARIA into an unfortunate predicament.

The weaker financial status of most startups, combined with the relatively thorough approach of big pharma towards trials can tax the balance sheet.